Background and Objectives Bipolar disorder (BD) may result in a greater burden than all forms of cancer, Alzheimer's disease and epilepsy. Cost-of-illness (COI) studies provide useful information on the economic burden that BD imposes on a society. Furthermore, COI studies are pivotal sources of evidence used in economic evaluations. This study aims to give a general overview of COI studies for BD and to discuss methodological issues that might potentially influence results. This study also aims to provide recommendations to improve practice in this area, based on the review. Methods A search was performed to identify COI studies of BD. The following electronic databases were searched: MEDLINE, EMBASE, PsycInfo, Cochrane Database of Systematic Reviews, HMIC and openSIGLE. The primary outcome of this review was the annual cost per BD patient. A narrative assessment of key methodological issues was also included. Based on these findings, recommendations for good practice were drafted. Results Fifty-four studies were included in this review. Because of the widespread methodological heterogeneity among included studies, no attempt has been made to pool results of different studies. Potential areas for methodological improvement were identified. These were: description of the disease and population, the approach to deal with comorbidities, reporting the rationale and impact for choosing different cost perspectives, and ways in which uncertainty is addressed. Conclusions This review showed that numerous COI studies have been conducted for BD since 1995. However, these studies employed varying methods, which limit the comparability of findings. The recommendations provided by this review can be used by those conducting COI studies and those critiquing them, to increase the credibility and reporting of study results.
Introduction

Bipolar Disorder
Bipolar disorder (BD), also commonly known as bipolar affective disorder, manic-depressive illness or affective psychosis, is a severe mental illness characterized by periods of elevated mood and periods of depression [1] . A recent 11-nation survey [2] shows that about 2.4 % of people around the world have had a diagnosis of BD at some point in their lifetime. More than half of those BD patients noted that the illness began in their adolescent years.
More than a decade ago, a World Health Organization report [3] suggested that BD resulted in a greater burden than all forms of cancer, Alzheimer's disease and epilepsy. Patients with BD are more likely to have higher rates of health service use and mental and physical comorbidities [2, 4, 5] , as well as increased suicide attempts, substance misuse, sexual risk behaviour and social dysfunction [4, [6] [7] [8] [9] . Individuals with BD have significantly greater use of medical services, and this condition also imposes a financial burden on both the individuals it affects and their families, employers and society as a whole [6, [10] [11] [12] ].
Cost-of-Illness Studies
Cost-of-illness (COI) studies do not determine the most appropriate course of action with respect to the disease studied as such studies are not evaluative [6] . Nevertheless, they do provide useful information on the magnitude of the impact of an illness on society or a part of society. This information can highlight aspects of the disease and processes of care where improvements are needed, and thus inform planning of healthcare services and the prioritisation of research [13] . Furthermore, COI studies provide a framework and important evidence for cost estimation in economic evaluations. The key methodological points to consider when reviewing a COI study include: definition of the disease and population, epidemiological approach, perspective of the analysis, cost component, costing method and sensitivity analysis [14] [15] [16] [17] . A more detailed description of each of the key points, and their relevance to BD is reported in Appendix 1, electronic supplementary material.
Objectives
Numerous COI studies have been published for BD in the past 20 years. However, interpreting the results of these studies can be difficult, owing to the diversity in study design and reporting. The purpose of this review is to give a general overview of these studies and to discuss methodological issues that might potentially influence results. Based on the results of this review, we provide recommendations to improve the quality and reporting of COI studies for BD.
Methods
Search Methodology
The search was performed on 11 October 2013 to identify COI studies of BD. The following databases were searched: MEDLINE (including in-process and other nonindexed), EMBASE, PsycInfo (1806 to October Week 2 2013), Cochrane Database of Systematic Reviews, System for Information on Grey Literature (openSIGLE) and Health Management Information Consortium (HMIC). The search strategy included the following Medical Subject Heading terms and text words: bipolar disorder, schizoaffective psychosis, mania, hypomania and cyclothymia, in combination with the following health economics terms: cost of illness, cost analysis, health care cost, hospital cost and burden. No language, date or country restrictions were applied to the search. The detailed search strategy is reported in electronic supplementary material, Table 2 .
Selection of Studies
Inclusion and exclusion criteria were defined a priori. Studies were included if (1) the population of interest was children/young people/adults with a clinical diagnosis of BD or its related disorders; and (2) the cost impact of BD was reported or could be derived. Studies were excluded if (1) they referred to costs of interventions only; (2) the direct healthcare cost for patients with BD was not reported and cannot be derived; (3) the participants of the study were not representative of the general BD population; and (4) reviews, commentaries or editorials.
Two reviewers performed the first screening of the literature search results, by comparing titles and abstracts to the inclusion criteria. The full articles were then obtained for possibly useful studies and checked against the inclusion criteria. Final inclusion of studies in the review was determined by agreement of both reviewers.
The bibliographies of published review/overview papers identified from the search were checked to ensure that all relevant COI studies have been retrieved by the search strategy used.
Presentation of Results
The primary measure reported was the annual cost per BD patient, which includes direct healthcare cost, production losses and other costs. For the purposes of consistency, all total costs have been converted to 2013 US dollars using a web-based tool: http://eppi.ioe.ac.uk/costconversion/ default.aspx [18] . Cost per patient is used instead of the total cost to the country because it is recognised that the total cost to one country largely depends on the local incidence and prevalence, and thus may not be applicable to another country. Furthermore, many studies only reported the cost per patient rather than total cost to the country. When cost per patient is not reported, it was calculated by the authors, when data allowed. Because of substantial heterogeneity among included studies, no attempt has been made to pool together results of different studies. A narrative assessment of key methodological issues such as perspective of cost, study method, epidemiological approach and data source is also included.
Draft Recommendations
Based on the review findings, we have made recommendations about how to improve the quality and reporting of COI studies for BD, considering what approaches are typically adopted, the advantages and disadvantages of the adopted method and their potential impacts on the results, and how methods could be improved.
Results
The detailed results of the literature search are reported in electronic supplementary material, Table 3 . After deduplication, a total of 877 titles and abstracts were reviewed, and 127 full articles were retrieved. Of these, 54 satisfied predefined inclusion criteria and were included. The inter-reviewer agreement was 88.5 % (776/877). Figure 1 illustrates the literature selection process.
The bibliographies of 20 published review/overview papers [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] were checked to ensure all relevant COI studies were included in this review.
A summary of the characteristics of included studies is reported in Table 1 . Most included studies were published since 2000 (51/54, 94.4 %). Around 60 % (32/54) of studies were from the USA. The sample size of included studies ranges from 40 [39] to 67,862 [40] . Most included studies (50/54, 92.6 %) assessed the cost impact of adult BD patients, while only four studies examined the cost impact for other age groups. Three studies looked at children and adolescents [41] [42] [43] , while one study assessed older patients aged over 60 years [44] .
Most included studies (46/54, 85.2 %) reported the annual costs of BD. One study [45] reported 2-year costs, while another two studies [46, 47] reported 21-month costs; all of which were converted to annual costs by the authors of this review. Of the remaining studies, two reported lifetime costs of BD [9, 10] while the other three studies reported the cost of treating one manic episode [48] [49] [50] .
The methods and cost estimates of all included studies are reported in electronic supplementary material, Table 4 .
Defining the Disease and Population
Different disease terms were used in the included studies: BD (35 studies), BD I (five studies), BD I and II (one study), BD or manic disorder (one study), manic-depressive disorder (one study) and affective disorder (one study). Forty-three studies reported that they used Diagnostic and Statistical Manual of Mental Disorders or International Classification of Diseases codes for BD, while 11 studies did not specify which diagnostic criteria was used.
Because of the heterogeneity of the included studies, it is impossible to compare results of studies looking at different subtypes of BD. Nevertheless, some included studies provided comparisons. For example, a recent Australian study [9] reported that the total lifetime cost per patient for BD I, BD II and unipolar depression was $160,671, $94,401, and $95,584, respectively (2012 Australian dollars). Two other studies also show that BD I is associated with higher total costs compared with other subtypes of BD [51, 52] .
Four studies found that the cost for patients with BDdepressive is higher than BD-manic, BD-mixed or BDunknown [11, [53] [54] [55] . However, two other studies showed different results; one US study [53] examined the claim records of 6,148 patients with new episodes of BD, and found that patients diagnosed as BD-manic had higher BDrelated treatment costs ($19,317, 2002 US dollars; p \ 0.01) compared with individuals diagnosed as depressive ($11,452), mixed ($10,012) or other/unknown ($15,589). Another US study [56] assessed the paid claims for 3,349 California Medicaid patients, and found that compared with BD-unspecified, a diagnosis of BD-mixed and BD-manic were associated with costs that were higher by $3,780 (1999 US dollars, p \ 0.0001) and $2,459 (p = 0.0033), respectively.
Other than disease subtype, the following factors are reported to be associated with higher treatment costs: delayed diagnosis or misdiagnosis [56] [57] [58] [59] ; patients with frequent psychiatric interventions [41, 60, 61] ; use of second-generation antipsychotics [40, 62] ; non-adherence to antipsychotic treatment [46, 63, 64] ; patients with poor prognosis [10] ; patients who relapsed [47] ; and patients with multiple comorbidities [43, 65] , such as drug abuse, cerebral-vascular disease, ischaemic heart disease, hypertension [40, 62] and diabetes mellitus [52] .
Comorbidities
The cost impact of comorbidities is substantial. Eight included studies reported separate cost estimates for BD-or psychiatric-related costs and total cost. All eight studies were conducted in the USA. Three studies [11, 51, 53] did not provide details about how to separate BD costs from all-cause costs. Another three studies [52, 60, 61] used the principal/primary diagnosis listed on claims to separate BD-specific cost from all-cause costs. The percentages of BD-related cost reported by these three studies are: 18.6 % [52], 41.0 % [60] and 49.0 % [61] . Two other studies [40, 62] adopted a broader definition of BD-related cost, and counted all medical claims with any codes for BD, or any claims where use was made of mental health tests/services/ drugs. Interestingly, the percentages of BD-related costs to all-cause costs reported by these two studies are lower than two of the three studies [60, 61] , which only considered a primary diagnosis of BD: 30 % [62] and 33 % [40] .
Despite the impact of comorbidities, none of the included studies provided a clear framework as to which comorbidities should be considered in estimating the costs of BD and how much of the comorbidity costs are attributable to BD. Seven studies considered comorbidity scores or specific type of comorbidities as confounding factors in regression analysis [40, 42, 43, 52, 57, 62, 65] . One study compared the cost of BD patients with and without metabolic conditions [66] . Begley et al. [10] is the only study that calculated separate cost for comorbidities; however, this study only considered the cost of excess alcohol (ethanol) and drug abuse and did not justify why other common comorbidities of BD such as anxiety were not considered in their study.
Epidemiological Approach
Eight out of the 54 studies adopted an incidence-based approach or a variant of this [9, 10, 52, 53, 56, 59, 67, 68] . Among these eight studies, six reported the short-term cost impact of newly diagnosed BD [52, 53, 56, 59, 67, 68] , while the other two studies reported lifetime costs of BD [9, 10] . For the six incidence-based studies that examined the short-term cost impact of BD, three compared the cost before and after BD diagnosis [52, 53, 59] , and found that although the post-diagnosis cost was generally higher than the pre-diagnosis cost, there was not a large difference between the two periods. One incidence-based study [68] analysed trends in hospital admissions for patients admitted with a BD diagnosis for the first time, and found that their total costs were almost the same in 1997 compared with [10] developed a cost model that estimated the total and per case lifetime cost of BD for 1998 incident cases in the USA. It was assumed that there were five alternative prognoses for BD patients: responsive stable, nonresponsive, nonresponsive chronic, fluctuating responsive and fluctuating nonresponsive. The resource use pattern for each prognosis group was estimated by expert consensus. Age-and sex-specific incidence rates of BD in 1998 were estimated by simulation based on existing prevalence data. The magnitude of the lifetime costs of persons with an onset of BD in 1998 was estimated at US$24 billion. The average cost per case ranged from US$11,720 for persons with a single manic episode to US$624,785 for persons with nonresponsive/chronic episodes.
Parker et al. [9] did not measure the costs from diagnosis until recovery or death. Instead, this study assessed the cost since the age of illness onset to diagnosis. Patients who were diagnosed as having BD at a Sydney tertiary care centre were asked to complete an assessment booklet, which included a series of questions and scales investigating the resource use related to BD since illness onset. Based on these self-reported data, this study estimated that the total lifetime cost (direct and indirect) was $160,671 (2012 Australian dollars) for BD I disorder, $94,401 for BD II disorder and $95,584 for unipolar disorder. However, Parker et al. [9] did not provide details as to how cost derived from the assessment booklet was extrapolated over a patient's lifetime. Furthermore, neither Begley et al. [10] nor Parker et al. [9] described how costs vary over the course of the disease.
Forty-six studies used the prevalence-based approach or variants of this approach. It is noticeable that some of the prevalence-based approach studies have very small sample sizes. Caution needs to be taken when extrapolating the results of such studies to the whole BD population.
Discounting
Discounting was only considered in four included studies [10, 12, 69, 70] . Both Rice et al. [69] and Das Gupta et al. [12] aimed to assess annual costs of BD, and they only applied discounting to production losses (3 % and 6 %, respectively). Begley et al. [10] and an Australian report [70] applied discounting (3 and 0.81 %, respectively) to all future costs. It is noticeable that the discount rate adopted by the Australian report [70] (0.81 %) is particularly low. It is reported that the 0.81 % discount rate is calculated based on the 30-year average growth of real average weekly 
Perspective of the Analysis and Costs Assessed
Of the 54 studies included in this review, 14 adopted a broadly societal perspective. However, non-medical costs such as prison costs and police and legal costs were only considered in six studies.
A health system perspective is considered to be more relevant to healthcare commissioners, and was adopted by nine studies. The rest of the included studies adopted institutional (eight studies), institutional and patient (eight studies), insurance (seven studies), insurance and patient (six studies), employer (one study), and employer and patient (one study) perspectives.
Estimating Resource Consumption
Twelve included studies used a top-down approach, 36 studies used a bottom-up approach, five studies used an econometric approach [11, 45, 66, 71, 72] and one study used a consolidated approach [70] . Most top-down studies used aggregate data from multiple sources, such as national surveys, government health databases and published literature. In contrast, most bottom-up studies used patientlevel data obtained from claims database, patient registries, hospital records or patient interviews. It is noticeable that some bottom-up studies using data from a single institution or patient interviews had very small sample sizes and thus might not represent the whole BD population. For example, Roijen et al. [39] only interviewed 40 patients to calculate the societal costs of BD.
One Australian study [70] adopted both a top-down and bottom-up approach, and found out that there was an 11-fold difference between direct costs of BD estimated using a top-down approach ($1,151 per person or $114 million nationally, 2003 Australian dollars) and the bottom-up approach ($12,946 per person or $1.3 billion nationally). The study suggested two main reasons for such a difference. First, the top-down approach assumes that all BD patients are receiving best practice treatment. However, a national survey shows that one-third of BD patients received no treatment while 40 % were not taking medication. Therefore, the top-down approach might significantly underestimate the cost of relapse due to non-adherence. Second, high rates of comorbidities, misdiagnosis and delayed diagnosis were not captured adequately in the top-down data. As a consequence, the authors decided to adopt a consolidated approach taking into account allowances for these factors. The resulting figures were $2,855 per person or $287 nationally, which was 2.5 times of the results of the original top-down approach, but only 22 % of the bottom-up approach figure.
Prospective or Retrospective Cost of Illness
All included studies are retrospective except Hong et al. [46] and Hong et al. [47] .
Direct Healthcare Costs
It is important to ensure that only costs attributable to BD are counted in COI studies. However, there are two challenges in isolating the additional healthcare costs due solely from BD: (a) the high prevalence of comorbidities and (b) 'background cost'. The comorbidity issues have been discussed in Sect. 3.2. 'Background costs' are those that would occur regardless of the presence of BD, such as routine health checks and age-or sex-related problems. Comparison groups can be used to address background cost issues. Of the 54 studies included in this review, nine of them used a matched control group.
All included studies considered inpatient hospital costs, which remain a large component of the overall direct costs. However, five studies [43, 48, 64, 68, 73] only considered inpatient hospital cost. Other cost components commonly considered in COI studies include: outpatient and community care, nursing home stays, medication and emergency department visits.
It is noted that most US studies (25/32, 78.1 %) used claims data to assess direct healthcare cost. The potential problems of this approach are that claims data are often expensive to get access to and that many assumptions need to be made when using claims data, such as clinical diagnoses being accurate, medical codes being entered correctly and that a prescription filled is a prescription used.
Production Loss
Of the 54 studies included in this review, only 16 studies considered production loss.
The ratio of production losses to total cost varied from 20 % [74] to 94 % [58] . This variation can be potentially explained by different methods used for the estimation of both direct healthcare costs and production losses.
Four areas of heterogeneity have been identified in terms of estimating production losses. First, some studies only considered direct healthcare cost and production loss while other studies also considered the cost to criminal justice services. This does not affect the magnitude of the production losses but does affect the proportion of the total they account for. Second, there are differences in the type of production loss included. For those 16 studies that assessed production losses, eight studies considered both morbidity and mortality costs while five studies only considered morbidity costs. Third, who the costs fall on was treated differently. Five studies considered the production loss for BD patients and their carers, while the other 11 studies only considered the production loss for patients. Finally, most studies used the HCA to value lost time while one study used the FCA [39] .
Other Costs
Only six studies [12, 58, 69, 70, 75, 76] considered costs other than direct healthcare cost and production losses: all of them reported costs to the criminal justice service, while two studies reported costs of supported living and social housing [75, 76] .
Intangible Costs
None of the included studies have assigned monetary values to intangible costs.
Sensitivity Analysis
The results of sensitivity analyses were only reported in seven included studies [12, 46, 47, 49, 58, 77, 78] . The healthcare direct cost of BD was reported to be sensitive to the following variables: number of inpatient episodes, number of contacts with community mental health teams [12] , daily cost of full-time and part-time day hospitalisation, and the daily cost of rest homes [49] . One study found that their healthcare cost estimate was generally robust to all scenarios tested, which included different medication options (anti-obesity preparations and psycho-stimulants) and general practitioner-initiated tests [77] . Das Gupta et al. [12] reported that production cost is sensitive to changes in the number of unemployed people with BD, but not sensitive to the excess rate of absenteeism from work or the number of people committing suicide. Runge et al. [58] reported that production loss is sensitive to the prevalence of BD and unemployment rate.
Discussion
Summary of Results
This review identified several factors associated with higher direct healthcare costs. These include:
• BD I [9, 51, 52] • delayed diagnosis or misdiagnosis [56] [57] [58] [59] • frequent psychiatric interventions [41, 60, 61] • use of second-generation antipsychotics [40, 62] • non-adherence to antipsychotic treatment [46, 63, 64] • poor prognosis [10] • relapse [47] • multiple comorbidities [40, 43, 52, 62, 65] It is recognised that the costs of BD fall on many different parts of society other than the healthcare system, such as individuals with BD and their families, local councils, the tax bureau and the criminal justice system. Because only 26 % of included studies took a societal perspective, much less evidence is available about factors associated with higher societal costs:
• BD I [9] • delayed diagnosis or misdiagnosis [58] • poor prognosis [10] Based on the above findings, substantial savings could potentially be achieved by increasing investment in the following areas:
• interventions targeted at BD I • education programmes for improved diagnosis (especially differential diagnosis), and earlier intervention • treatment of mental and physical comorbidities • greater adherence to medications and use of psychotherapies, such as assertive community psychiatric intervention and augmentation of specialist outpatient services [70] Some included studies (e.g. Parker et al. [9] ) show that production losses, especially mortality costs are substantial and can be substantially greater than the direct medical costs, which indicate that implementation of interventions that can prevent suicide or address BD at the level of the workplace could be effective in reducing the total costs.
Methodological issues
Comorbidities
Merikangas et al. [79] reported that three-quarters of BD patients also met the diagnostic criteria for another lifetime disorder, with more than half having at least three other comorbidities, and with anxiety being the most predominant other condition. Therefore, neglecting comorbidities is likely to cause significant underestimation of the cost of BD.
How to address the cost of comorbidity is particularly an issue for those studies using bottom-up approaches. Some of the included US studies tried to alleviate this problem by reporting separate outcomes for all-cause costs and costs related to BD or other psychiatric disorders. However, neither cost is a true reflection of the actual cost of BD, as the all-cause cost tends to overestimate the true cost (because it assumes that all expenditure that occurs with BD patients is entirely attributable to BD, not to any other comorbidities), while BD-related cost is likely to underestimate the true cost (as it only consider claims with a primary diagnosis of BD).
Comorbidities might be less an issue for those studies using traditional top-down or econometric approaches as ideally, the comorbidity costs that are attributable to BD would have already been captured by population-attributable fraction (for top-down approach) or by comparison to a matched control group who do not have BD (econometric approach). Some included studies adopted a variant of a top-down approach, as although they used aggregate data to calculate COI, they did not measure the proportion of the total expenditure that is attributable to BD. Such studies are likely to overestimate the total cost impact of BD.
Alternative methods are available for calculating costs attributable to the disease of interest. These include attributable risk analysis, econometric analysis [16] or a weighted approach [80] , which involves defining a set of explicit decision rules that can be used to identify the proportion of the cost that should be attributed to BD The decision rules can be based on a diagnosis-related group, and the presence of other BD-related and/or non-related diagnoses.
Incidence-or Prevalence-Based Studies
Most of the included studies (46/54, 85.2 %) adopted a prevalence-based approach. Such studies only need to collect data for 1 year, and nothing needs to be known or assumed about the future course of BD. Incidence-and prevalence-based studies will give similar results if the costs all occur in 1 year [16] . With BD this is unlikely to be the case, except for those with a single episode and no long-term consequences. If the decision makers are only interested in taking a snapshot of the current costs of BD, then the prevalence approach might be sufficient. However, for decision makers interested in knowing the future disease burden of BD and the potential savings that can be made from preventing BD, the incidence approach would be more appropriate.
However, BD is a chronic disease that may last for a patient's lifetime. It will thus be very difficult to conduct an incidence-based study that covers the whole disease and care pathway. One potential solution is to conduct a number of prevalence-based studies that examine different stages of BD; and use these discrete studies to inform the estimation of lifetime costs. Another potential solution is to use expert opinions to project future disease incidence, resource use patterns and survival data for BD patients with different prognoses [10] .
Production Loss
BD is associated with high rates of unemployment and jobrelated difficulties. A survey conducted in the USA [81] showed that approximately 60 % of individuals with BD were unemployed, even among patients with college degrees. Furthermore, 88 % of participants reported occupational difficulties. This finding is supported by evidence from European countries. Dittmann et al. [82] found that in Germany, only 30 % of patients with BD were employed full time at a level that was appropriate for their qualifications. An Italian study [23] found that more than 60 % of patients with BD I were unemployed. In the UK, the rate of excess absenteeism from work caused by BD is assumed to be 8 % [12] .
Of the 54 studies included in this review, only 16 of them considered production losses. The reported percentage contribution of production loss to total costs ranges from 20 % [74] to 94 % [58] . This suggests that the total cost reported by studies that only look at direct healthcare costs will have been substantially underestimated.
Of the 16 included studies that reported production losses, eight considered both morbidity and mortality costs. However, the inclusion of mortality-related production losses in COI studies can be controversial. Because mortality costs are based on the future loss of earnings, the time frame of this measurement in prevalence studies is inconsistent with that of other costs, which are normally measured for only 1 year. Furthermore, the value of losses owing to mortality is highly sensitive to the data and assumptions upon which they are based, such as predictions about future employment rates and labour market participation, all of which are subject to a high degree of uncertainty. Therefore, it is suggested that mortality-related production losses be subjected to sensitivity analyses and be reported separately from morbidity costs.
Unit Cost Data
Many included studies used charges to value resource use. One potential problem of this is that charges may not reflect the true value of resources. For example, charges may underestimate true costs if they only reflect a copayment. Commissioners of healthcare service (such as insurance companies in the USA or the National Health Service in the UK) can negotiate prices and receive substantial discounts off listed charges. COI studies using listed charges might overestimate the cost of an illness. A potential solution of this is to adjust the unit cost using a cost-to-charge ratio [16] .
Reporting
Of the 54 studies included in this review, many did not report details about diagnostic criteria used, how comorbidity costs were considered, which method was used to estimate resource use (e.g. top-down, bottom-up or their variants) or production losses (HCA, FCA or willingnessto-pay). A clear statement of the study methods can improve comparability between COI studies [13] .
Recommendations for Good Practice
The following section presents recommendations on how to improve the quality and reporting of COI studies for BD, along with justifications. The recommendations could potentially be used by researchers performing the COI studies for BD, authors writing a description of the methodologies and results, and stakeholders wishing to understand the most important issues that influence the validity of a COI study. The recommendations can also be used to help stakeholders to understand the most important issues that influence the validity of a COI study. The recommendations are indicators and not all items will be relevant in all contexts.
Defining the Disease and Population
• How BD is defined can have considerable influence over the magnitude of cost estimates. Ideally, the diagnoses of BD should be based on objective criteria, such as Diagnostic and Statistical Manual of Metnal Disorders or the International Classification of Diseases. Ambiguous terms such as affective disorder and manic-depressive disorder should be avoided.
• Patient characteristics, such as subtype of BD, comorbidities, treatment history and prognosis should be clearly reported. When appropriate, separate cost estimates need to be reported for different patient subgroups.
Comorbidities
• Attributable risk analysis, econometric analysis [16] or a weighted approach [80] can be used to estimate the attributable costs of BD.
• The selection of co-morbid diseases attributable to BD should be based on best evidence.
Epidemiological Approach
If the decision makers are only interested in taking a snapshot of the current costs of BD, then the prevalence approach would be sufficient. However, for decision makers interested in knowing the future disease burden of BD and the potential savings that can be made from preventing BD, the incidence approach should be adopted, as it can reflect cost trend from the onset of BD till recovery or death. Prevalence-based COI studies need to have a sufficient sample size to improve the validity of the study.
Discounting
• COI studies should reflect the present value of the stream of costs accruing over the time horizon of the analysis. Therefore, for COI studies with a time horizon longer than 1 year, a discount rate published by a reliable source should be applied. When there is uncertainty of the value of discount rate, sensitivity analyses should be conducted; and a range of possible cost estimates should be presented.
Perspective of the Analysis and Costs Assessed
• COI studies that adopt a comprehensive perspective should apportion the costs by stakeholders so as to allow analysis from multiple perspectives.
Estimating Resource Consumption
• When the top-down approach is used, factors such as adherence to guideline recommendations, comorbidities, misdiagnosis and delayed diagnosis need to be considered.
• Caution should be taken when extrapolating personbased study results, as the participants may not accurately represent the general BD population.
• If possible, both top-down and bottom-up approaches can be adopted. The results of both approaches can be compared with each other.
Prospective or Retrospective COI
• More prospective COI studies of BD should be conducted.
Direct Healthcare Costs
• Direct costs associated with treatment of BD should include inpatient hospitalisation, outpatient and community care, nursing home, medication and substance abuse treatment.
• Ways to control the 'background noise' should be adopted such as the inclusion of a matched control group and regression analysis.
Production Loss
• Decision makers need to be clear about which method was used to estimate production loss, and what types of production loss have been included, as these factors might have a dramatic effect of the cost estimates.
• If mortality-related production losses are calculated, they should be reported separately, and tested by sensitivity analysis.
Other Costs
• For those COI studies that adopt a societal perspective, the following indirect costs need to be included: costs to the criminal justice services (incarceration, policing, legal and costs to victims of crime) [84] , cost of supported living and social housing, and cost of disrupted/ lost education.
Intangible Costs
• If intangible costs are not reported, the COI study should note that intangible costs have been omitted.
Sensitivity Analysis
• It is recommended that sensitivity analyses should be conducted to test all important parameters and key assumptions used in COI studies, and a range of possible cost estimates should be reported [85] .
Limitations
There are several limitations of COI studies [86] . First, although a COI study can help to identify areas of high expenditure, it does not provide information about the efficiency of resource allocation in such areas. Furthermore, some expensive areas might not necessarily amenable to current available treatment. Second, sometimes the COI estimate is used as a proxy of ''potential cost savings'' of either fully or partially preventing BD. However, few COI studies would consider the costs of prevention, which could be much greater than the treatment cost. In addition, not all costs of BD can be saved by prevention. Therefore, although COI studies are useful in highlighting the magnitude of the impact of BD and attracting public attention, further research such as costeffectiveness or cost-utility analysis is needed, to inform resource allocation decisions.
Conclusion
This review has reported the widespread heterogeneity in the methodologies applied in published COI studies in the area of BD. It has highlighted a number of factors that might have a large impact on the cost estimates. Based on the review findings, recommendations about good practice for BD COI studies have been suggested. These recommendations can be used to improve the quality and reporting of COI studies and help stakeholders to critically appraise, and correctly interpret the results of studies.
